**EXHIBIT 10.30 B**
**FIRST AMENDMENT TO THE LICENSE AGREEMENT**
     **This First Amendment to the License Agreement** (the “Amendment”) is made and enteredinto as of April 26, 2002 (the “Amendment Completion Date”), by and between **The University ofKansas Center for Research, Inc.,**a Kansas not-for-profit corporation (“Licensor”), and**ProQuest Pharmaceuticals, Inc.,** a Kansas corporation (“Licensee”). Licensor and Licenseemay be referred to herein as a “Party” or, collectively, as “Parties”.
**Recitals**
     **Whereas,**Licensor and Licensee entered into a License Agreement (the “Agreement”)effective April 2, 1999, wherein Licensor granted Licensee an exclusive license under certainproprietary cyclic peptide and prodrug technology to develop, make, use and sell products; and
     **Whereas,**the Parties desire to amend the terms of the Agreement as provided in thisAmendment to change the royalty payments due Licensor under such license grant in consideration forthe payment by Licensee of certain ongoing expenses for the filing and maintenance of patents innon-United States countries as of the Amendment Effective Date.
**Now, Therefore,** the Parties agree as follows:
**1.****Amendment of the Agreement**
     The Parties hereby agree to amend the terms of the Agreement as provided below, effective asof the Amendment Effective Date. To the extent that the Agreement is explicitly amended by thisAmendment, the terms of the Amendment will control where the terms of the Agreement are contrary toor conflict with the following provisions. Where the Agreement is not explicitly amended, theterms of the Agreement will remain in force. Capitalized terms used in this Amendment that are nototherwise defined herein shall have the same meanings as such terms are defined in the Agreement.
     **1.1. Amendment of Article 1 of the Agreement.**A new Paragraph 1.12 and a new Paragraph 1.13are added to Article 1 of the Agreement, reading in their entirety as follows:
“1.12 **“Effective Date”**means April 2, 1999.
“1.13 “**Amendment Effective Date”**means February 6, 2002.
     **1.2. Amendment of Paragraph 3.01 of the Agreement.**Paragraph 3.01 of the Agreement is herebydeleted and replaced in its entirety as follows:
     “3.01 As consideration for the license granted to Licensee by Licensor under thisAgreement, Licensee shall pay to Licensor as royalties the following percentages of LicenseRevenue derived by Licensee for each patent:
1.

 
        **Patent or Application**  **Percentage of License Revenue**  U.S. Patent No. 5,672,584  2.0%  Water Soluble Prodrugs of Tertiary AmineContaining Drugs and Methods of MakingThereof (“Tertiary and Secondary AminePatent”)  2.0%  Water Soluble Prodrugs of Hindered Alcohols(“Alcohol and Phenol Patent”)  2.0%  
                                        **(i)**No royalties shall be owed in connection with an individual patent listed aboveuntil a United States patent application is issued from the United States Patent andTrademark Office with respect to that patent. From the Effective Date until the issuance ofthe Tertiary and Secondary Amine Patent and the Alcohol and Phenol Patent, Licensee shallrecord and maintain complete and accurate records of License Revenue potentially allocableto each such Existing Application. If the Existing Applications issue as patents, thenLicensee shall pay to Licensor such percentage of License Revenue allocable as above to eachsuch issued patent as is or has been received by Licensee for the period beginning on theEffective Date and ending as set forth in subsection (ii) below.
                                        **(ii)**Subject to Paragraph 7.04, royalties due under this Paragraph 3.01 shall bepayable on a country-by-country and Product-by-Product (as applicable) basis until theexpiration, nullification, final judgment of invalidity or abandonment after exhaustion ofall appeals of the last-to-expire, last-to-be nullified, last-to-be held invalid or last tobe abandoned claim of an issued patent under the Patent Rights or under the ExistingApplications in such country covering a Product or other applicable License Revenue.
     **1.3. Amendment of Paragraph 7.01 of the Agreement.**The last sentence of Paragraph 7.01 of theAgreement is hereby deleted in its entirety.
     **1.4. Amendment of Paragraph 7.03 of the Agreement.**Paragraph 7.03 of the Agreement is herebydeleted and replaced in its entirety with the following:
“7.03 Reimbursement for Foreign Patent Costs.
          (i) Subject to Paragraph 7.04, Licensee shall reimburse Licensor for allreasonable costs and expenses incurred after the Amendment Effective Date andassociated with the filing, prosecution and maintenance of Patent Rights innon-United States countries as are: (a) agreed upon in writing by the parties, (b)generated through compliance by the parties with Paragraph 7.02 and (c) actuallyincurred by Licensor and not reimbursed by Third Parties. Licensee shall reimbursesuch amount within thirty (30) days of receipt from Licensor of an invoice itemizingand documenting such costs and expenses.
2.

 

          (ii) Upon completion of Licensee’s Phase 1 Financing, Licensee shall promptlyreimburse Licensor for reasonable costs and expenses associated with the filing andprosecution of Patent Rights in non-United States countries as were: (a) agreed uponin writing by the Parties or agreed upon in writing by ProQuest (as may be evidencedby Licensor’s receipt of invoice from patent counsel for expenses directed byProQuest) and (b) actually incurred by Licensor and not reimbursed by Third Partiesfor the period beginning on the Effective Date and ending on the Amendment EffectiveDate. Within thirty (30) days following the Amendment Completion Date, the Licensorshall provide to the Licensee a written estimate prepared in good faith thatsummarizes such costs and expenses. Licensee shall have the right to audit andverify the invoices and relevant documents that support such costs and expenses.Licensee shall reimburse Licensor for such filing and patent costs as set forth inthis subsection (ii) in four (4) equal payments. The first such payment shall be duewithin sixty (60) days of the completion of Licensee’s Phase 1 Financing, and thesubsequent three (3) payments shall be made, respectively, at four (4) monthintervals thereafter.
     **1.5 Amendment of Paragraph 7.04 of the Agreement.**Paragraph 7.04 of the Agreement is herebydeleted and replaced in its entirety with the following:
          “7.04 Pursuant to Paragraph 9.03, Licensee may terminate its payment obligations underParagraphs 7.01 and 7.03 as to all Patent Rights or as to any jurisdiction or any part ofthe Patent Rights upon ninety (90) days prior written notification to Licensor of suchtermination. If Licensee so elects, then both the scope of the license grant in Article 2and the payment obligations under Paragraphs 3.01, 7.01 and 7.03 shall be narrowedaccordingly. Nothing in this section shall relieve Licensee of its obligation to reimburseLicensor for all expenses of any Patent Rights incurred by Licensor prior to the surrenderby Licensee of such Patent Rights.”
     **1.6 Amendment of Paragraph 17.01 of the Agreement.**The contact information for Licensee andLicensor stated in Paragraph 17.01 of the Agreement is hereby revised to read as follows:       If to Licensor: The University of Kansas Center for Research, Inc.    Youngberg Hall    Lawrence, Kansas 66044         Executive Director of Technology Transfer    Attention:  James G. Baxendale    Telephone: (785) 864-7783    Facsimile:   (785) 864-5272       With a copy to: Corporate Counsel    Attention: Arjun S. Sanga    Telephone: (785)864-4148
3.

 
         Facsimile:   (785) 864-5272       If to Licensee: ProQuest Pharmaceuticals, Inc.    1201 Wakarusa Drive, Building E, Suite 2    Lawrence, Kansas 66049    Attention: Osborne Wong    Telephone: (785) 865-1585       With a copy to: Cooley Godward LLP    3000 El Camino Real    Palo Alto, California 94306-2155    Attention: Barclay James Kamb, Esq.    Telephone: (650) 843- 5052    Facsimile:   (650) 849-7400
**2.** **Miscellaneous**
     **2.1 Full Force and Effect.**This Amendment amends the terms of the Agreement and is deemedincorporated into, and governed by all other terms of, the Agreement. The provisions of theAgreement, as amended by this Amendment, remain in full force and effect.
     **2.2 Counterparts.**This Amendment may be executed in two or more counterparts, each of whichshall be deemed an original, but all of which together shall constitute one and the sameinstrument.
     **In Witness Whereof,**the Parties have executed this Amendment in duplicate originalsby their authorized officers as of the Amendment Completion Date, and such Amendment is effectiveas of the Amendment Effective Date.           **The University of Kansas Center for**      **Research, Inc.**               By:                                                                           Title:Vice President                       **ProQuest Pharmaceuticals, Inc.**               By:/s/ Osborne S. Wong                       Title:President            
4.